JP2017506234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506234A5 JP2017506234A5 JP2016550786A JP2016550786A JP2017506234A5 JP 2017506234 A5 JP2017506234 A5 JP 2017506234A5 JP 2016550786 A JP2016550786 A JP 2016550786A JP 2016550786 A JP2016550786 A JP 2016550786A JP 2017506234 A5 JP2017506234 A5 JP 2017506234A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- drug conjugate
- amino acid
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1402009.3 | 2014-02-06 | ||
| GB201402009A GB201402009D0 (en) | 2014-02-06 | 2014-02-06 | Antibody-drug conjugates and immunotoxins |
| PCT/EP2015/052342 WO2015118031A2 (en) | 2014-02-06 | 2015-02-04 | Antibody-drug conjugates and immunotoxins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506234A JP2017506234A (ja) | 2017-03-02 |
| JP2017506234A5 true JP2017506234A5 (enExample) | 2018-03-15 |
| JP6616776B2 JP6616776B2 (ja) | 2019-12-04 |
Family
ID=50390520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550786A Active JP6616776B2 (ja) | 2014-02-06 | 2015-02-04 | 抗体−薬物複合体及び免疫毒素 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10004812B2 (enExample) |
| EP (1) | EP3102606B1 (enExample) |
| JP (1) | JP6616776B2 (enExample) |
| KR (1) | KR102342934B1 (enExample) |
| CN (1) | CN105980411B (enExample) |
| CA (1) | CA2937600C (enExample) |
| DK (1) | DK3102606T3 (enExample) |
| ES (1) | ES2701188T3 (enExample) |
| GB (1) | GB201402009D0 (enExample) |
| HU (1) | HUE040517T2 (enExample) |
| PL (1) | PL3102606T3 (enExample) |
| WO (1) | WO2015118031A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016077451A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| WO2018187158A1 (en) * | 2017-04-07 | 2018-10-11 | Tracon Pharmaceuticals, Inc. | Combination therapy of cancer with anti-endoglin antibodies and anti-programmed death receptor agents |
| US20200165350A1 (en) * | 2017-06-01 | 2020-05-28 | Health Research, Inc. | Strong potentiation of immune checkpoint blockade therapy of cancer by combination with endoglin-targeting therapy |
| FI3666787T3 (fi) | 2017-08-10 | 2024-03-15 | Sumitomo Pharma Co Ltd | Hemiasterliinijohdannaisen sisältäviä vasta-aine-lääkekonjugaatteja |
| US12018093B2 (en) | 2017-08-10 | 2024-06-25 | Sumitomo Pharma Co., Ltd. | Hemiasterlin derivatives and antibody-drug conjugates including same |
| JP2017214419A (ja) * | 2017-08-18 | 2017-12-07 | 学校法人関西医科大学 | 白血病改善剤 |
| US11998584B2 (en) * | 2017-12-31 | 2024-06-04 | Hangzhou Dac Biotech Co., Ltd. | Conjugate of a tubulysin analog with branched linkers |
| EP3898089A1 (en) | 2018-12-18 | 2021-10-27 | 3M Innovative Properties Company | Coated abrasive articles and methods of making coated abrasive articles |
| JP7560255B2 (ja) * | 2019-02-13 | 2024-10-02 | 住友ファーマ株式会社 | ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬 |
| CA3127312A1 (en) | 2019-02-13 | 2020-08-20 | Sumitomo Dainippon Pharma Co., Ltd. | Hemiasterlin derivative having cysteine residue |
| JP7479302B2 (ja) | 2019-02-13 | 2024-05-08 | 住友ファーマ株式会社 | ヘミアスタリン誘導体とその抗体薬物複合体 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| EP4537854A1 (en) * | 2023-10-04 | 2025-04-16 | Formosa Laboratories, Inc. | Compound for conjugation, conjugate and pharmaceutical composition comprising the same |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025141153A1 (en) * | 2023-12-29 | 2025-07-03 | Oncomatryx Biopharma, S.L. | Endo180 targeted antibody-drug conjugates |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5660827A (en) * | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
| US7097836B1 (en) * | 2002-10-23 | 2006-08-29 | Health Research, Inc. | Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody |
| EP2489372A3 (en) * | 2007-03-14 | 2013-01-02 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
| WO2008138561A1 (en) * | 2007-05-10 | 2008-11-20 | R & D Biopharmaceuticals Gmbh | Tubulysine derivatives |
| US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| KR20120080611A (ko) * | 2009-10-06 | 2012-07-17 | 이뮤노젠 아이엔씨 | 효능 있는 접합체 및 친수성 링커 |
| WO2012135517A2 (en) * | 2011-03-29 | 2012-10-04 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
| US9255595B2 (en) * | 2011-04-29 | 2016-02-09 | Bae Systems Information And Electronic Systems Integration Inc. | Optical dome bezel |
| IN2014CN04961A (enExample) | 2011-12-05 | 2015-09-18 | Igenica Biotherapeutics Inc | |
| ES2781523T3 (es) | 2012-07-12 | 2020-09-02 | Hangzhou Dac Biotech Co Ltd | Conjugados de moléculas de unión celular con agentes citotóxicos |
| EP3099681B1 (en) | 2014-01-28 | 2020-12-09 | TUBE Pharmaceuticals GmbH | Cytotoxic tubulysin compounds and conjugates thereof |
-
2014
- 2014-02-06 GB GB201402009A patent/GB201402009D0/en not_active Ceased
-
2015
- 2015-02-04 PL PL15705779T patent/PL3102606T3/pl unknown
- 2015-02-04 KR KR1020167021450A patent/KR102342934B1/ko active Active
- 2015-02-04 CN CN201580007513.8A patent/CN105980411B/zh active Active
- 2015-02-04 WO PCT/EP2015/052342 patent/WO2015118031A2/en not_active Ceased
- 2015-02-04 HU HUE15705779A patent/HUE040517T2/hu unknown
- 2015-02-04 CA CA2937600A patent/CA2937600C/en active Active
- 2015-02-04 ES ES15705779T patent/ES2701188T3/es active Active
- 2015-02-04 DK DK15705779.5T patent/DK3102606T3/en active
- 2015-02-04 JP JP2016550786A patent/JP6616776B2/ja active Active
- 2015-02-04 EP EP15705779.5A patent/EP3102606B1/en active Active
- 2015-02-04 US US15/116,419 patent/US10004812B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506234A5 (enExample) | ||
| JP2017506630A5 (enExample) | ||
| JP2020509027A5 (enExample) | ||
| JP2016523810A5 (enExample) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| JP2020525542A5 (enExample) | ||
| JP2019536740A5 (enExample) | ||
| JP2017534256A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| JP2017500028A5 (enExample) | ||
| JP2016538318A5 (enExample) | ||
| JP2016531915A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| JP2013510868A5 (enExample) | ||
| JP2017518040A5 (enExample) | ||
| JP5948525B1 (ja) | 癌のための併用療法 | |
| JP2015509947A5 (enExample) | ||
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JP2016502504A5 (enExample) | ||
| JP2017510661A5 (enExample) | ||
| JP2020500834A5 (enExample) | ||
| US20190194309A1 (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
| JP2020502271A5 (enExample) | ||
| JPWO2021177438A5 (enExample) | ||
| JP2025510606A (ja) | Ｂ７ｈ４抗体薬物複合体及びその使用 |